Targeting fundamentals of inflammation, autoimmunity and fibrosis
Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.
-
GRT-001
Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.
-
GRT-002
Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.
Two first-in-class therapeutic antibodies GRT-001 and GRT-002
2000
20 years of foundational research
In novel approaches for inflammation and fibrosis
2021
Lead assets and pipeline growth
Foundation of Granite Bio by Versant Ventures and Novartis Venture Fund (NVF), integrated into the Ridgeline Discovery Engine. 30 Million USD Series A Financing
2022
Preclinical Development/CMC
Development Candidates achieved.
2023
Series B & CTA submission
70 Million USD Series B Financing led by Forbion and Sanofi ventures, completion of CTA enabling studies and CTA submission.
2024
Phase 1 / 1b
Clinical trial approval by the German health authorities (Paul-Ehrlich-Institute, PEI) to initiate Ph1(b) trial of GRT-001 in healthy volunteers and patients with inflammatory bowel disease (IBD). First Ph1 participants dosed March 6 at CRO Charité Berlin, Germany.
About Granite Bio:
Team:
Granite Bio Team:
-
Nigel Sheail
-
Dominik Hartl
Chief Medical Officer
grey+roche grey+quell grey+novartis -
Kerry Thornton
Executive Assistant
grey+roche grey+vector -
Thomas Huber
VP Biology
grey+novartis grey+almirall -
Kerstin Renner
Head Translational Medicine
grey+ukr -
Sofia Forte
Head Clinical Operations
grey+novartis -
Sara Belli
Head Clinical Pharmacology
grey+roche -
Jean-Nicolas Schickel
Head Immunology Discovery
grey+evotecgrey+vectorgrey+sanofi -
Georgios Sarantis
Senior Clinical Trial Manager
grey+novartis grey+pfizer -
Maria Sfichiu
Clinical Trial Manager
grey+sgs grey+idorsia -
Giorgio Ferrari
Associate Scientist Immunology
grey+actelion -
Olivia Rudin
Senior Research Associate
grey+cimeio grey+limmatech grey+idorsia -
Hasan-Halit Oz
Senior Scientist Immunology
grey+yale -
Sonia Whitlow
Toxicology Study Monitor
Check out our lastest job posts:
Ridgeline Team (supporting Granite Bio):
-
Guillaume Daniel
BD&L
-
Andrew Jefferson
Operations
grey+roche -
Giorgio Ottaviani
Preclinical Pharmacology / Toxicology
-
Kai Rosport
CMC
-
Mohammed Ullah
Preclinical Pharmacology / DMPK
Board of Directors:
-
Laia Crespo
Sanofi Ventures
grey+sanofiventures -
Markus Enzelberger
Versant Ventures
grey+versant -
Alexander Mayweg
Versant Ventures
grey+versant -
Matthias Mack
Co-founder
grey+ukr -
Florian Müllershausen
Novartis Venture Fund
grey+nvf -
Rogier Rooswinkel
Forbion
grey+forbion
Scientific Advisors:
-
Vishwa Deep Dixit
Yale University
Innate Immunity -
Christopher Denton
University College London
Fibrosis -
Jörg Distler
Düsseldorf University
Fibrosis -
Erica Herzog
Yale University
Pulmonary Fibrosis -
Brian Feagan
Ontario, Canada
Inflammatory Bowel Disease -
Florian Rieder
Cleveland Clinic
Inflammatory Bowel Disease -
Scott Brian Snapper
Boston/Harvard University
Inflammatory Bowel Disease -
Eric Solary
Paris - Saclay University
Leukemia (CMML)